Էստոնիա - էստոներեն - Ravimiamet

sandoz pharmaceuticals d.d. - darunaviir - õhukese polümeerikattega tablett - 800mg 120tk; 800mg 30tk; 800mg 240tk; 800mg 60tk; 800mg 90tk; 800mg 10tk

Էստոնիա - էստոներեն - Ravimiamet

sandoz pharmaceuticals d.d. - darunaviir - õhukese polümeerikattega tablett - 75mg 90tk; 75mg 480tk; 75mg 120tk; 75mg 30tk; 75mg 60tk; 75mg 10tk

Էստոնիա - էստոներեն - Ravimiamet

teva b.v. - darunaviir - õhukese polümeerikattega tablett - 400mg 60tk; 400mg 200tk; 400mg 20tk

Էստոնիա - էստոներեն - Ravimiamet

sandoz pharmaceuticals d.d. - darunaviir - õhukese polümeerikattega tablett - 400mg 10tk; 400mg 60tk; 400mg 90tk; 400mg 30tk

Էստոնիա - էստոներեն - Ravimiamet

sandoz pharmaceuticals d.d. - darunaviir - õhukese polümeerikattega tablett - 600mg 120tk; 600mg 180tk; 600mg 240tk; 600mg 90tk; 600mg 10tk

Էստոնիա - էստոներեն - Ravimiamet

teva b.v. - darunaviir - õhukese polümeerikattega tablett - 800mg 90tk; 800mg 100tk; 800mg 10tk

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Էստոնիա - էստոներեն - Ravimiamet

accord healthcare b.v. - ritonaviir - õhukese polümeerikattega tablett - 100mg 30tk; 100mg 120tk; 100mg 90tk

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, fluticasone propionaat - astma - ravimid hingamisteede obstruktiivsete haiguste, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.